The Elimination Status of Visceral Leishmaniasis in Southeast Asia Region

IF 1.2 3区 农林科学 Q4 PARASITOLOGY
Samiur Rahim, Muhammad Manjurul Karim
{"title":"The Elimination Status of Visceral Leishmaniasis in Southeast Asia Region","authors":"Samiur Rahim,&nbsp;Muhammad Manjurul Karim","doi":"10.1007/s11686-024-00880-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Visceral leishmaniasis (VL) is caused by an intracellular parasite that is transmitted to humans by sandfly bites. It is prevalent throughout Asia, Africa, the Americas, and the Mediterranean area, where 147 million people are at risk of contracting the illness. The manifestation of heterotrophic illness relies on both <i>Leishmania</i> implicated and the host’s immunological response, ranging from asymptomatic to severe leishmaniasis with potentially lethal effects.</p><h3>Method</h3><p>We reviewed the literature (published till 31st December 2023) on the worldwide situation of leishmaniasis, standard and novel detection techniques, and traditional and modern treatment strategies and endeavors to eliminate VL. Moreover, epidemiological data was collected from the World Health Organization’s publicly available databases. GraphPad Prism Version 8 was used to analyze and produce figures based on the epidemiological data.</p><h3>Results</h3><p>Diagnosis of parasites in tissues or serology is commonly employed. Diagnosis by identifying parasite DNA using molecular techniques is becoming more popular. Despite recent findings of <i>L. donovani</i> resistance to pentavalent antimoniate medications, it continues to be the cornerstone in the medical management of VL. Amphotericin B and its lipid formulations, injectable paromomycin, and oral miltefosine are among the new therapy options being researched. The number of reported VL cases has reduced remarkably over the last decade due to human interventions made to eliminate VL. Particularly countries from the South East Asian region have experienced momentous progress in reducing VL cases and eliminating this disease from this region. Owing to the robust elimination programs, countries such as Bangladesh has eliminated VL as a public health concern. India and Nepal are on the verge of its elimination.</p><h3>Conclusion</h3><p>Rapid diagnosis, effective and inexpensive treatment, simple access to newly discovered medications, appropriate vector control, and a well-designed vaccine are all required for the elimination of this disease burden in impoverished areas of the globe.</p></div>","PeriodicalId":6932,"journal":{"name":"Acta Parasitologica","volume":"69 3","pages":"1704 - 1716"},"PeriodicalIF":1.2000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Parasitologica","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s11686-024-00880-5","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Visceral leishmaniasis (VL) is caused by an intracellular parasite that is transmitted to humans by sandfly bites. It is prevalent throughout Asia, Africa, the Americas, and the Mediterranean area, where 147 million people are at risk of contracting the illness. The manifestation of heterotrophic illness relies on both Leishmania implicated and the host’s immunological response, ranging from asymptomatic to severe leishmaniasis with potentially lethal effects.

Method

We reviewed the literature (published till 31st December 2023) on the worldwide situation of leishmaniasis, standard and novel detection techniques, and traditional and modern treatment strategies and endeavors to eliminate VL. Moreover, epidemiological data was collected from the World Health Organization’s publicly available databases. GraphPad Prism Version 8 was used to analyze and produce figures based on the epidemiological data.

Results

Diagnosis of parasites in tissues or serology is commonly employed. Diagnosis by identifying parasite DNA using molecular techniques is becoming more popular. Despite recent findings of L. donovani resistance to pentavalent antimoniate medications, it continues to be the cornerstone in the medical management of VL. Amphotericin B and its lipid formulations, injectable paromomycin, and oral miltefosine are among the new therapy options being researched. The number of reported VL cases has reduced remarkably over the last decade due to human interventions made to eliminate VL. Particularly countries from the South East Asian region have experienced momentous progress in reducing VL cases and eliminating this disease from this region. Owing to the robust elimination programs, countries such as Bangladesh has eliminated VL as a public health concern. India and Nepal are on the verge of its elimination.

Conclusion

Rapid diagnosis, effective and inexpensive treatment, simple access to newly discovered medications, appropriate vector control, and a well-designed vaccine are all required for the elimination of this disease burden in impoverished areas of the globe.

Abstract Image

东南亚地区消除内脏利什曼病的现状。
目的:内脏利什曼病(VL)由一种细胞内寄生虫引起,通过沙蝇叮咬传播给人类。它流行于亚洲、非洲、美洲和地中海地区,那里有 1.47 亿人面临患病风险。异养病症的表现取决于利什曼原虫和宿主的免疫反应,从无症状到可能致命的严重利什曼病不等:方法:我们查阅了有关利什曼病的全球状况、标准和新型检测技术、传统和现代治疗策略以及消除 VL 的努力的文献(截至 2023 年 12 月 31 日)。此外,还从世界卫生组织的公开数据库中收集了流行病学数据。使用 GraphPad Prism Version 8 对流行病学数据进行分析并制作图表:通常采用组织或血清学方法诊断寄生虫。通过使用分子技术鉴定寄生虫 DNA 进行诊断正变得越来越流行。尽管最近发现唐诺沃伊蚊对五价抗锑药物有抗药性,但五价抗锑药物仍是治疗 VL 的基石。两性霉素 B 及其脂质制剂、注射用巴龙霉素和口服米替福新都是正在研究的新疗法。在过去十年中,由于人类为消除 VL 而采取的干预措施,报告的 VL 病例数量已显著减少。特别是东南亚地区的国家在减少 VL 病例和消灭该疾病方面取得了重大进展。由于实施了强有力的消除计划,孟加拉国等国已经消除了作为公共卫生问题的 VL。印度和尼泊尔也即将消灭这一疾病:结论:快速诊断、有效而廉价的治疗、简单获得新发现的药物、适当的病媒控制以及精心设计的疫苗,这些都是在全球贫困地区消除这一疾病负担所必需的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Parasitologica
Acta Parasitologica 医学-寄生虫学
CiteScore
3.10
自引率
6.70%
发文量
149
审稿时长
6-12 weeks
期刊介绍: Acta Parasitologica is an international journal covering the latest advances in the subject. Acta Parasitologica publishes original papers on all aspects of parasitology and host-parasite relationships, including the latest discoveries in biochemical and molecular biology of parasites, their physiology, morphology, taxonomy and ecology, as well as original research papers on immunology, pathology, and epidemiology of parasitic diseases in the context of medical, veterinary and biological sciences. The journal also publishes short research notes, invited review articles, book reviews. The journal was founded in 1953 as "Acta Parasitologica Polonica" by the Polish Parasitological Society and since 1954 has been published by W. Stefanski Institute of Parasitology of the Polish Academy of Sciences in Warsaw. Since 1992 in has appeared as Acta Parasitologica in four issues per year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信